MX339564B - Sistemas de liberacion pulsatil sincronizada. - Google Patents

Sistemas de liberacion pulsatil sincronizada.

Info

Publication number
MX339564B
MX339564B MX2013002257A MX2013002257A MX339564B MX 339564 B MX339564 B MX 339564B MX 2013002257 A MX2013002257 A MX 2013002257A MX 2013002257 A MX2013002257 A MX 2013002257A MX 339564 B MX339564 B MX 339564B
Authority
MX
Mexico
Prior art keywords
lag
coating
medications
beads
profiles
Prior art date
Application number
MX2013002257A
Other languages
English (en)
Inventor
Gopi Venkatesh
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of MX339564B publication Critical patent/MX339564B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)

Abstract

Se describe una forma de dosis unitaria de partículas múltiples para la distribución de uno o más ingredientes farmacéuticos activos, básicos, al cuerpo en necesidad de tales medicamentos, para lograr perfiles farmacocinéticos (PK) objetivo. La forma de dosis comprende una o más partículas de fármaco multirrecubiertas (esferas, pellas, mini-/micro-tabletas) que tienen un recubrimiento de barrera y un recubrimiento de tiempo de retardo. Cada población de esferas de Liberación Pulsátil Sincronizada (TPR) muestra un tiempo de retardo predeterminado, seguido por diferentes característica de liberación. La composición y el espesor de recubrimiento de barrera, la composición y el espesor del recubrimiento de tiempo de retardo, la proporción de las esferas IR a una o más de las poblaciones de esferas TPR y la dosis total pueden ser variadas dependiendo de la alcalinidad, la solubilidad dependiente del pH y la vida media de eliminación de los ingredientes activos, para lograr los perfiles de PK objetivo (adecuados para el régimen de dosificación una vez al día o dos veces al día) en pacientes en necesidad de tales medicamentos.
MX2013002257A 2005-05-02 2006-05-01 Sistemas de liberacion pulsatil sincronizada. MX339564B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/120,139 US9161918B2 (en) 2005-05-02 2005-05-02 Timed, pulsatile release systems
PCT/US2006/016538 WO2006119153A2 (en) 2005-05-02 2006-05-01 Timed, pulsatile release systems

Publications (1)

Publication Number Publication Date
MX339564B true MX339564B (es) 2016-05-31

Family

ID=37234728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002257A MX339564B (es) 2005-05-02 2006-05-01 Sistemas de liberacion pulsatil sincronizada.

Country Status (10)

Country Link
US (7) US9161918B2 (es)
EP (2) EP1879556B1 (es)
JP (5) JP5059748B2 (es)
AU (1) AU2006242308B2 (es)
CA (3) CA2963382A1 (es)
ES (2) ES2568746T3 (es)
HK (1) HK1108116A1 (es)
MX (1) MX339564B (es)
NZ (2) NZ602823A (es)
WO (1) WO2006119153A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
MX2009001711A (es) * 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Formulaciones de liberacion sostenida de topiramato.
EP2197448A4 (en) * 2007-09-12 2010-11-17 Elan Pharma Int Ltd dosing schedule
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
ES2459322T3 (es) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
US20120128764A1 (en) * 2009-02-23 2012-05-24 Aptalis Pharmatech, Inc. Controlled-release compositions comprising a proton pump inhibitor
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
SG10201407947WA (en) 2009-11-30 2015-01-29 Aptalis Pharmatech Inc Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
RU2563623C2 (ru) 2009-12-02 2015-09-20 Апталис Фарма Лимитед Микрокапсулы фексофенадина и содержащие их композиции
EP2547206B1 (en) * 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
PL2672981T3 (pl) 2011-02-11 2018-09-28 Zx Pharma, Llc Wielocząstkowe preparaty l-mentolu i powiązane sposoby
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2014516080A (ja) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
SI2659881T1 (en) 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
KR20150046310A (ko) * 2012-08-29 2015-04-29 샐릭스 파마슈티컬스 인코포레이티드 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
JP5919173B2 (ja) * 2012-11-22 2016-05-18 全星薬品工業株式会社 徐放性塩酸アンブロキソール口腔内崩壊錠
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US20160030412A1 (en) * 2013-02-26 2016-02-04 Ari AZHIR Compositions and methods for treatment in parkinson's disease patients
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
PL2872123T3 (pl) 2013-04-23 2017-06-30 Zx Pharma, Llc Kompozycja wielocząstkowa olejku z mięty pieprzowej z otoczką dojelitową o kontrolowanym uwalnianiu i powiązane sposoby
EP3019160A1 (en) * 2013-07-09 2016-05-18 Sun Pharmaceutical Industries Ltd Extended-release pharmaceutical compositions of metoprolol
ES2905267T3 (es) 2013-07-11 2022-04-07 Tasly Pharmaceutical Group Co Composición de medicina tradicional china, y preparación y aplicación de la misma
CA2916423C (en) 2013-07-11 2021-10-26 Tasly Pharmaceutical Group Co., Ltd. Formulation of a micro drop pill and the preparation method thereof
EP3020407A4 (en) 2013-07-11 2017-05-03 Tasly Pharmaceutical Group Co., Ltd. Traditional chinese medicine composition, and preparation and application thereof
WO2015017423A2 (en) * 2013-07-29 2015-02-05 Aptalis Pharmatech, Inc. Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104418744B (zh) 2013-08-29 2017-03-01 天士力制药集团股份有限公司 一种新的丹酚酸化合物t、其制备方法和用途
EP3062776A1 (en) * 2013-10-29 2016-09-07 Tillotts Pharma AG A delayed release drug formulation
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103961326A (zh) * 2014-04-18 2014-08-06 赵辉 一种依西美坦口腔崩解片及其制备方法
CN103948570A (zh) * 2014-04-18 2014-07-30 赵辉 一种依西美坦缓释胶囊
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
JP6956009B2 (ja) * 2014-12-29 2021-10-27 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 化学療法剤の多段階放出のための組成物、装置、および方法
TWI830686B (zh) * 2016-07-06 2024-02-01 友霖生技醫藥股份有限公司 含有藥物組成物、障礙層及藥物層之口服劑型
WO2019046251A1 (en) 2017-08-28 2019-03-07 Adare Pharmaceuticals, Inc. TIZANIDINE FORMULATIONS
WO2019071272A1 (en) 2017-10-06 2019-04-11 Adare Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP4176724A1 (en) 2021-11-09 2023-05-10 Universität Hohenheim Use of an oleogel as a layer or coating

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
JPS4111273Y1 (es) 1964-04-01 1966-05-25
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
JPS4969819U (es) 1972-10-02 1974-06-18
US4078051A (en) 1973-02-05 1978-03-07 L'oreal Cross-linked starch coated antiperspirant derivative of aluminum, process for its preparation and antiperspirant composition containing same
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1561204A (en) 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
JPS55129224A (en) 1979-03-27 1980-10-06 Toyo Jozo Co Ltd Fine granules having improved taste
JPS5614098A (en) 1979-07-13 1981-02-10 Takeda Chem Ind Ltd Externally lubricating tablet making machine
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4292017A (en) 1980-07-09 1981-09-29 Doepel Wallace A Apparatus for compressing tablets
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
CA1181430A (en) 1980-11-14 1985-01-22 Bennie J. Foster (-) - n-methyl-3-(2-methylphenox)-3-phenylpropylamine, antidepressant
US4587118A (en) 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
JPS5916821A (ja) 1982-07-16 1984-01-28 Tanabe Seiyaku Co Ltd 非凝集性マイクロカプセルの製法
US4698101A (en) 1982-08-30 1987-10-06 Suomen Sokeri Oy (Finnish Sugar Company Ltd.) Binder-diluent composition and method
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
EP0153105B1 (en) * 1984-02-10 1992-09-09 Benzon Pharma A/S Diffusion coated multiple-units dosage form
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
ZA854876B (en) 1984-06-28 1986-08-27 Searle & Co Antacid composition
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
FR2571045B1 (fr) 1984-10-03 1987-12-11 Roquette Freres Mannitol granulaire directement compressible et son procede de fabrication
US4670459A (en) 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
FR2571046B1 (fr) 1984-10-03 1987-10-16 Roquette Freres Procede de preparation de mannitol granulaire directement compressible
JPH0653658B2 (ja) 1984-12-17 1994-07-20 中外製薬株式会社 安定な錠剤の製造法
DE3505433A1 (de) 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen Direkttablettierhilfsmittel
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPS6261916A (ja) 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
SE455836B (sv) 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
GB8530365D0 (en) 1985-12-10 1986-01-22 Univ Bath Manufacture of moulded products
DE3684446D1 (de) * 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
JPH0774153B2 (ja) 1986-04-14 1995-08-09 三共株式会社 ロキソプロフェン・ナトリウム含有製剤
US4786508A (en) 1986-05-30 1988-11-22 Warner-Lambert Company Coated dosage forms
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4757090A (en) 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
IT1200217B (it) 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
JPS63162619A (ja) 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
KR910002669B1 (ko) 1986-12-25 1991-05-03 데이산세이야꾸 가부시끼가이샤 서방성 과립 및 그를 함유하는 지속성 복합과립
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4874613A (en) 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
GB8710965D0 (en) 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
KR960011236B1 (ko) 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4824675A (en) 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4983508A (en) * 1987-11-18 1991-01-08 Fuji Photo Film Co., Ltd. Method for manufacturing a light-sensitive silver halide emulsion
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5211957A (en) 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
ATE82680T1 (de) 1988-05-04 1992-12-15 Smith Kline French Lab Kautablette.
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
IL91398A (en) 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8824392D0 (en) 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
US5256699A (en) 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
HU200926B (en) 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
DK0382489T3 (da) 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
ES2044246T3 (es) * 1989-02-11 1994-01-01 Bayer Ag Medicamentos con liberacion controlada del producto activo.
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US4946684A (en) 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5013557A (en) 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
FR2655266B1 (fr) 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
IT1238078B (it) 1990-01-31 1993-07-05 Silvano Spinelli Cis-platino complessi con ammine e sulfinilcarbossilati chelanti
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JP2781442B2 (ja) 1990-02-19 1998-07-30 旭化成工業株式会社 顆粒含有錠剤
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
ZA919510B (en) 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
EP0516345A1 (en) 1991-05-28 1992-12-02 Eli Lilly And Company Use of nizatidine for the manufacture of a medicament for the treatment of reflux esophagitis
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
GB9113487D0 (en) 1991-06-21 1991-08-07 Amersham Int Plc Agents for hypoxic cells
US5252337A (en) 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
JP3586471B2 (ja) 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 トラセミド含有医薬組成物
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
CA2079934C (en) 1991-10-15 2002-09-03 Edward J. Roche Taste mask coatings for preparing chewable pharmaceutical tablets
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
AU666509B2 (en) 1991-12-24 1996-02-15 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
ATE147261T1 (de) 1992-01-13 1997-01-15 Pfizer Verfahren zur herstellung von tabletten mit hoher festigkeit
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
DE627218T1 (de) 1992-02-18 1995-08-24 Nippon Shinyaku Co Ltd Schnelllösliche tablette.
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
JPH05310558A (ja) 1992-05-07 1993-11-22 Lion Corp 固形製剤組成物
TW271400B (es) 1992-07-30 1996-03-01 Pfizer
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
JPH08510989A (ja) 1992-10-16 1996-11-19 グラクソ、グループ、リミテッド ラニチジン組成物
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB9224855D0 (en) 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3319625B2 (ja) 1993-05-12 2002-09-03 ホーユー株式会社 速崩壊性生薬製剤
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JP2936376B2 (ja) 1993-09-03 1999-08-23 小林化工株式会社 ニコランジル錠剤の製法
JP2681601B2 (ja) 1993-11-01 1997-11-26 協和醗酵工業株式会社 外部滑沢式打錠機
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
DE4412117A1 (de) 1994-04-08 1995-10-12 Fette Wilhelm Gmbh Verfahren und Vorrichtung zum Aufbringen von pulverförmigem Schmier- oder Trennmittel auf die Preßwerkzeuge in Tablettiermaschinen
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5609883A (en) 1994-09-16 1997-03-11 Advanced Technology Pharmaceuticals Corporation Compressed tablet transitory lubricant system
GB9421837D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AU2931997A (en) 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1997047287A1 (fr) 1996-06-14 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Comprime intra-oral a desintegration rapide
JP3708291B2 (ja) 1996-06-21 2005-10-19 協和醗酵工業株式会社 微量粉体吐出装置及びこの装置を用いた微量粉体噴霧方法
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9182498A (en) 1997-10-03 1999-04-27 Elan Corporation, Plc Taste masked formulations
EP0914823B1 (de) 1997-11-06 2004-12-08 Lannacher Heilmittel Ges.m.b.H. Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6221402B1 (en) 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
FR2771292B1 (fr) 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
JPH11169437A (ja) 1997-12-03 1999-06-29 Kyowa Hakko Kogyo Co Ltd 錠剤の製造方法
DK1058538T3 (da) 1998-03-06 2002-10-21 Eurand Int Hurtigt desintegrerende tabletter
JP4237405B2 (ja) 1998-03-09 2009-03-11 シーマ・ラブス、インコーポレイテッド 集成体
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
CA2328100C (en) 1998-04-10 2011-01-18 Kyowa Hakko Kogyo Co. Ltd. Tablet production method and tablet
CN1148171C (zh) 1998-04-17 2004-05-05 大正制药株式会社 多单元缓释片剂
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
FR2778848B1 (fr) * 1998-05-20 2001-11-23 Prographarm Lab Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6099865A (en) 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
EP2020229A1 (en) 1998-11-02 2009-02-04 Elan Pharma International Limited Multiparticulate modified release composition
US6296868B1 (en) 1998-11-19 2001-10-02 Advanced Technology Pharmaceuticals Corporation Chewable tablets containing mannitol and aspartame
US6740341B1 (en) 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
AU2161000A (en) 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
US6039979A (en) 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
AU3071300A (en) 1999-01-21 2000-08-07 Elan Corporation, Plc Multiparticulate bisoprolol formulation
FR2790387B1 (fr) 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
IT1311977B1 (it) 1999-03-25 2002-03-22 Ausimont Spa Composizioni idro-oleo repellenti.
WO2000059486A2 (en) 1999-04-07 2000-10-12 Pfizer Products Inc. Use of cyp2d6 inhibitors in combination therapies
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
AU6715600A (en) 1999-08-26 2001-03-19 Elan Corporation, Plc Pharmaceutical formulations
DE19961897A1 (de) 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20030104066A1 (en) 2000-03-27 2003-06-05 Kouji Murai Easy-to-take granules
EP1277730A4 (en) 2000-03-28 2005-03-16 HEMMER OF NEOVASCULARIZATION
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
EP1276470B1 (en) 2000-04-20 2007-05-02 Novartis AG Taste masking coating composition
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6350471B1 (en) 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20020077348A1 (en) 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
JP2002154948A (ja) 2000-11-22 2002-05-28 Eisai Co Ltd 崩壊性に優れた錠剤
AU2002222567B2 (en) 2000-12-01 2007-05-10 Kyowa Hakko Kirin Co., Ltd. Composition improved in solubility or oral absorbability
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
GB2387597B (en) 2001-01-22 2004-11-10 Council Scient Ind Res Stereoselective preparation of 3-hydroxy-3-phenylpropionitrile
JP5502254B2 (ja) 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
WO2002069933A1 (fr) 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Comprimés à délitement rapide dans la bouche
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US20030096791A1 (en) 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
EP1423104A1 (en) 2001-08-08 2004-06-02 Eli Lilly And Company Combination therapy for the treatment of neurological disorders
WO2003026612A2 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
NZ532907A (en) 2001-11-21 2007-05-31 Eisai R & D Man Co Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CZ12993U1 (cs) 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
GB0129117D0 (en) 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
WO2004009058A1 (en) 2002-07-17 2004-01-29 Eurand Pharmaceuticals Ltd Process for the preparation of pharmaceutical microcapsules with enhanced taste-masking and high dissolution rate
BR0312876A (pt) 2002-07-25 2005-06-28 Pharmacia Corp Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
AU2003259417A1 (en) 2002-09-04 2004-03-29 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004087111A1 (en) 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Oral taste masked pharmaceutical compositions
EP1715856B1 (en) 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
WO2005097064A2 (en) 2004-04-12 2005-10-20 Pfizer Products Inc. Taste-masked drugs in rupturing multiparticulates
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2009064457A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Corticosteroid compositions
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same

Also Published As

Publication number Publication date
JP2008540419A (ja) 2008-11-20
JP5059748B2 (ja) 2012-10-31
JP2017019858A (ja) 2017-01-26
US20120128771A1 (en) 2012-05-24
JP2019006809A (ja) 2019-01-17
AU2006242308A1 (en) 2006-11-09
US20160106683A1 (en) 2016-04-21
CA2606813C (en) 2015-07-07
JP2012153724A (ja) 2012-08-16
US20200069597A1 (en) 2020-03-05
CA2963382A1 (en) 2006-11-09
ES2428064T3 (es) 2013-11-05
AU2006242308B2 (en) 2013-09-26
JP6815358B2 (ja) 2021-01-20
EP2638899B1 (en) 2016-01-20
CA2884901C (en) 2017-06-06
US9161918B2 (en) 2015-10-20
JP2020059755A (ja) 2020-04-16
WO2006119153A2 (en) 2006-11-09
EP1879556A2 (en) 2008-01-23
US20160038431A1 (en) 2016-02-11
JP6457458B2 (ja) 2019-01-23
US9579293B2 (en) 2017-02-28
US9566249B2 (en) 2017-02-14
ES2568746T3 (es) 2016-05-04
CA2606813A1 (en) 2006-11-09
CA2884901A1 (en) 2006-11-09
US11147772B2 (en) 2021-10-19
US20190076369A1 (en) 2019-03-14
HK1108116A1 (en) 2008-05-02
US10045946B2 (en) 2018-08-14
US20060246134A1 (en) 2006-11-02
NZ591688A (en) 2012-10-26
US9161919B2 (en) 2015-10-20
US10500161B2 (en) 2019-12-10
NZ602823A (en) 2014-05-30
WO2006119153A3 (en) 2007-05-31
US20170112774A1 (en) 2017-04-27
EP2638899A1 (en) 2013-09-18
EP1879556B1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
MX339564B (es) Sistemas de liberacion pulsatil sincronizada.
CA2494234A1 (en) Methods and dosage forms for controlled delivery of paliperidone
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
MX2010008235A (es) Nueva dosificacion y formulacion.
MY136136A (en) Pharmaceutical compositions containing terbinafin and use thereof
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2002024203A3 (en) Controlled release formulations for oral administration
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
CA2516327A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
WO2012068076A3 (en) Pharmaceutical formulations containing soluble drugs
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
PH12021550251A1 (en) Pharmaceutical composition for oral administration
WO2021151442A3 (en) Methotrexate dosage form
WO2006030303A8 (en) Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea
CA2991719C (en) Pharmaceutical compositions
Cantoni et al. Formulation and evaluation of sustained release tablets containing antioxidants
WO2008147245A3 (fr) Composition pharmaceutique de proxodolol à libération contrôlée
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt